Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. META
2. P
3. ORCL
4. OKTA
5. SPY
6. MGM
7. NVDA
8. AKAM
9. MCD
10. ACAD

Go back to Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
(NASDAQ: NMRA) Delayed: 0.70 -0.03 (4.11%)
Previous Close $0.73    52 Week High $ 
Open $0.75    52 Week Low $ 
Day High $0.77    P/E N/A 
Day Low $0.69    EPS $ 
Volume 1,427,243